Vetpharma Profile
Key Indicators
- Authorised Capital ₹ 3.50 Cr
as on 03-07-2024
- Paid Up Capital ₹ 8.07 M
as on 03-07-2024
- Company Age 29 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 36.10 Cr
as on 03-07-2024
- Revenue 100.42%
(FY 2022)
- Profit -30.47%
(FY 2022)
- Ebitda -63.01%
(FY 2022)
- Net Worth -297.19%
(FY 2022)
- Total Assets -48.46%
(FY 2022)
About Vetpharma
The Corporate was formerly known as Vet-Pharma Nitro Products Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 3.50 Cr and a paid-up capital of Rs 8.07 M.
The company has closed loans amounting to ₹36.10 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Dilip Pimple, Uday Mukesh, and Mukesh Naik serve as directors at the Company.
- CIN/LLPIN
U24239MH1995PLC088169
- Company No.
088169
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
08 May 1995
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Vetpharma?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Dilip Pimple  | Director | 23-Feb-1998 | Current |
| Uday Mukesh | Director | 15-Mar-2002 | Current |
| Mukesh Naik | Additional Director | 05-Jul-2016 | Current |
Financial Performance of Vetpharma.
Vetpharma Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 100.42% increase. The company also saw a substantial fall in profitability, with a 30.47% decrease in profit. The company's net worth observed a substantial decline by a decrease of 297.19%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Vetpharma?
In 2021, Vetpharma had a promoter holding of 26.98% and a public holding of 73.02%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Uday Chemical Engineers And Projects LimitedActive 29 years 11 monthsDilip Pimple, Uday Mukesh and 1 more are mutual person
- Astere Greene Energy Private LimitedActive 9 years 4 months
Uday Mukesh and Mukesh Naik are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 26 Dec 2016 | ₹5.00 Cr | Satisfied |
Others Creation Date: 14 Mar 2016 | ₹6.40 Cr | Satisfied |
Others Creation Date: 10 Mar 2016 | ₹10.00 Cr | Satisfied |
How Many Employees Work at Vetpharma?
Unlock and access historical data on people associated with Vetpharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Vetpharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Vetpharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
